LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Danna JenningsSarah Huntwork-RodriguezMaurits F J M VissersVinay M DaryaniDolores DiazMarisa S GooJohn J ChenRomeo D MaciucaKyle FraserOmar S MabroukJeroen van de Wetering de RooijJules A A C HeubergerGeert Jan GroeneveldMarie T BorinAndrés Cruz-HerranzDanielle GrahamKimberly A Scearce-LevieJavier De VicenteAnastasia G HenryPeter ChinCarole HoMatthew D TroyerPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
At generally safe and well-tolerated doses, BIIB122 achieved substantial peripheral LRRK2 kinase inhibition and modulation of lysosomal pathways downstream of LRRK2, with evidence of CNS distribution and target inhibition. These studies support continued investigation of LRRK2 inhibition with BIIB122 for the treatment of PD. © 2023 Denali Therapeutics Inc and The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.